Cipla USA Recalls Cinacalcet Hydrochloride Tablets
Cipla USA, Inc. has issued a Class II recall for Cinacalcet Hydrochloride Tablets (30 mg). The recall is due to CGMP deviations identified during manufacturing.
Topics
Developing
- 899d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 899d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 899d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 899d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
OpenFDA
“FDA Drug Recall: Cipla USA, Inc.. Class II... Product: Cinacalcet Hydrochloride Tablets, 30 mg... Reason: CGMP Devia...”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade